News: Incyte Corp (INCY.OQ)
INCY.OQ on NASDAQ Stock Exchange Global Select Market
25.83USD
4:00pm EDT
25.83USD
4:00pm EDT
Price Change (% chg)
$2.42 (+10.34%)
$2.42 (+10.34%)
Prev Close
$23.41
$23.41
Open
$23.59
$23.59
Day's High
$26.21
$26.21
Day's Low
$23.59
$23.59
Volume
566,142
566,142
Avg. Vol
312,570
312,570
52-wk High
$26.21
$26.21
52-wk Low
$15.43
$15.43
Select another date:
Thu, Jun 13 2013
Lilly says arthritis pill effective in mid-stage study
- Eli Lilly and Co and Incyte Corp said their experimental drug was effective in reducing painful symptoms associated with rheumatoid arthritis after 52 weeks of treatment.
Lilly says arthritis pill effective in mid-stage study
June 13 - Eli Lilly and Co and Incyte Corp said their experimental drug was effective in reducing painful symptoms associated with rheumatoid arthritis after 52 weeks of treatment.
Incyte shares fall on fears over Jakafi-related infection
March 18 - Incyte Corp said a 75-year-old male patient taking its lead drug to treat a rare bone marrow disease developed a brain infection but that it was not immediately clear whether the drug, ruxolitinib, caused it.
Select another date:
- Incyte's CEO Discusses Q2 2013 Results - Earnings Call Transcript
- Incyte Corporation (INCY) Management Discusses Q2 2013 Results (Webcast)
- Johnson & Johnson's Blockbuster Candidate Simponi And Its Rivals
- Incyte Is Positioning For A Strong 2nd Half
- Will Coronado Biosciences Revolutionize Medicine?
- Incyte: Financial Projection And Stock Valuation
Press Releases
- New Data for JakafiĀ® (ruxolitinib) Presented at the 2012 American Society of Hematology Annual Meeting
- New Data for Jakafi (ruxolitinib) to Be Presented at the 2012 American Society of Hematology Annual Meeting
- Incyte to Present at the Oppenheimer 23rd Annual Healthcare Conference
- Incyte to Present at the 24th Annual Piper Jaffray Healthcare Conference
- Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis
- Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
- Incyte to Present at the Jefferies2012 Global Healthcare Conference (London)
- Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders on Launch of Jakafi and Lead Clinical Programs
- Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer
- Incyte to Report Third Quarter 2012 Financial Results on November 1

